|
Press Releases |
|
 |
|
Friday, July 25, 2025 |
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
雲頂新耀宣布配售股份 擬集資約15.725億港元 |
雲頂新耀有限公司(HKEX1952.HK)是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司,今日宣布以先舊後新配售22,561,000股,集資約15.725億港元,發行股份數占現有股本約6.87%, 占經擴大後的總股數約6.43%。 more info >> |
|
云顶新耀宣布配售股份 拟集资约15.725亿港元 |
云顶新耀有限公司(HKEX1952.HK)是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,今日宣布以先旧后新配售22,561,000股,集资约15.725亿港元,发行股份数占现有股本约6.87%, 占经扩大后的总股数约6.43%。 more info >> |
|
Tuesday, July 15, 2025 |
|
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力 |
今日雲頂新耀(01952.HK)股價表現亮眼,盤中最高價觸及73.4港元,再創新高。 more info >> |
|
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力 |
今日云顶新耀(01952.HK)股价表现亮眼,盘中最高价触及73.4港元,再创新高。 more info >> |
|
Friday, July 4, 2025 |
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
雲頂新耀發佈AI+mRNA平台新突破 重塑中國mRNA國際競爭格局 |
近期,雲頂新耀(HKEX: 1952.HK)在上海成功舉辦「2025雲頂新耀mRNA創新技術平台研發日」,系統展示其自主構建的AI+mRNA平台的最新進展,以及多個管線項目在腫瘤及自身免疫疾病治療中的前沿突破。 more info >> |
|
云顶新耀发布AI+mRNA平台新突破 重塑中国mRNA国际竞争格局 |
近期,云顶新耀(HKEX: 1952.HK)在上海成功举办“2025云顶新耀mRNA创新技术平台研发日”,系统展示其自主构建的AI+mRNA平台的最新进展,以及多个管线项目在肿瘤及自身免疫疾病治疗中的前沿突破。 more info >> |
|
Thursday, July 3, 2025 |
|
雲頂新耀公佈EVER001-1b/2a期階段性數據 專家看好其作為新一代BTK療法的潛力 |
7月1日,雲頂新耀(HKEX: 1952.HK)公佈其自主研發的共價可逆BTK抑制劑EVER001在治療原發性膜性腎病(pMN)的1b/2a期臨床研究中取得最新數據。 more info >> |
|
云顶新耀公布EVER001-1b/2a期阶段性数据 专家看好其作为新一代BTK疗法的潜力 |
7月1日,云顶新耀(HKEX: 1952.HK)公布其自主研发的共价可逆BTK抑制剂EVER001在治疗原发性膜性肾病(pMN)的1b/2a期临床研究中取得最新数据。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
富士通、実用的な量子計算の実現に向けて、1万量子ビット超の超伝導量子コンピュータの研究開発を開始
Aug 1, 2025 10:30: JST
|
|
|
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
Aug 1, 2025 11:00 JST
|
|
|
A Bold New Chapter Begins at CEO SUITE
Aug 1, 2025 10:00 HKT/SGT
|
|
|
CEO SUITE開啟嶄新篇章
Aug 1, 2025 10:00 HKT/SGT
|
|
|
Shoucheng's Capital Leap: Zhao Tianyang Drives 2025 Upswing
Aug 1, 2025 09:40 HKT/SGT
|
|
|
從黑馬投資人到產業引領者 趙天暘領銜首程控股迎來「投資豐收年」
Aug 1, 2025 09:40 HKT/SGT
|
|
|
从黑马投资人到资本引领者 赵天旸领衔首程控股开启“丰收年”
Aug 1, 2025 09:30 HKT/SGT
|
|
|
Fujitsu starts official development of plus-10,000 qubit superconducting quantum computer targeting completion in 2030
Aug 1, 2025 10:20 JST
|
|
|
Scipio Capital Advisors、資本調達により認定投資家にオルタナティブ資産の利回りを提供
Aug 1, 2025 09:00: JST
|
|
|
Scipio Capital Advisors 資本募集行動讓合格投資人觸及另類資產收益
Aug 1, 2025 08:00 HKT/SGT
|
|
|
GTJAI Successfully Issued the First Publicly Offered Digital Bond of a Chinese Securities Firm
Aug 1, 2025 00:00 HKT/SGT
|
|
|
國泰君安國際成功發行中資券商首筆公募數碼原生債券
Jul 31, 2025 23:50 HKT/SGT
|
|
|
Scipio Capital Advisors Capital Raise puts Alternative Asset Yield Within Reach of Accredited Investors
Jul 31, 2025 20:25: JST
|
|
|
Scipio Capital Advisors Capital Raise puts Alternative Asset Yield Within Reach of Accredited Investors
Jul 31, 2025 19:25 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|